CORE--OPTICS AND PHOTODYNAMIC THERAPY DOSIMETRY

核心B（光学和PDT剂量测定核心）的总体目标是 为PDT在临床和临床中的光输送提供支持， 实验室这包括光传输设备的设置 （激光、光纤、光束分裂器），用于临床和实验室 光动力疗法 PDT在实验室和临床都需要适当的剂量测定。核心 提供设备和人员支持项目的研究 并致力于最大化有用信息的产量。执行此 因此，有必要了解PDT的剂量学。这导致一个 努力塑造。对剂量测定的有限理解取决于 光和药物已经扩大了通过QSAR数据的研究 焦脱镁叶绿酸己基醚系列包括敏感的目标， PDT。我们打算继续研究PDT的剂量学， 支持并提供一个可测试的模型框架， 结构活动总体研究中其他项目的成果 关系。核心人员将进行激光维护、校准 以及临床和实验室要求的剂量测定 项目的研究活动。 核心B的具体目标是： I.为临床和科研激光提供技术支持; 二.治疗过程中光漂白的测量; 三.肿瘤和正常组织总衰减的测量 接受PDT治疗皮肤肿瘤的患者; 四.焦脱镁叶绿酸己基醚和苯甲酸的药代动力学研究 后续系列和ALA; v.肿瘤和正常组织的冷冻切片中的PS分布; 六.改进PDT靶向和剂量测定的分析框架。

The overall aim of Core B, the Optics and PDT Dosimetry Core, is to provide support for the light delivery for PDT both in the clinic and in the laboratory. This include the setup for the light delivery devices (lasers, fibers, beam splinters) for both clinical and laboratory photodynamic therapy. PDT in both the laboratory and clinic requires proper dosimetry. The Core provides equipment and personnel to support the research of the projects and works to maximize the yield of useful information. To perform this function it is necessity to understand the dosimetry of PDT. This leads an effort in modeling. The limited understanding of dosimetry as dependent on the light and a drug has been expanded through study of the QSAR data on the pyropheophorbide hexyl ether series to include a sensitive target for PDT. We intend to continue to study the dosimetry of PDT in an attempt to support and provide a testable model framework in which to understand the results of the other projects in the overall study of structure activity relationships. Core personnel will perform laser maintenance, calibration and dosimetric measurements required by the clinical and laboratory research activities of the projects. The specific aims of Core B are: i. Technical support for clinical and scientific lasers; ii. Measurement of photobleaching during therapy; iii. Measurement of the total attenuation of tumor and normal tissue in patients undergoing PDT for the treatment of skin tumors; iv. Study of the pharmacokinetics of pyropheophorbide hexyl ether and subsequent series and ALA; v. PS distributions in frozen sections of tumors and normal tissues; vi. Refining the analytic framework of PDT targeting and dosimetry.